İlginç bir hormon ilginç bir hastalık: hiperprolaktinemi ve prolaktinoma

Year 2019, , 561 - 576, 01.12.2019

Mustafa Taşdelen Şenay Durmaz Ceylan

https://doi.org/10.21601/ortadogutipdergisi.466911

Abstract

Prolaktin (PRL) hormonunun normalden daha yüksek miktarda salınımı olarak adlandırılan hiperprolaktinemi endokrinolojik tetkikler sırasında en sık rastlanılan patolojik durumdur. Hormon hipersekresyonuna neden olan hipofiz adenomlarının en sık karşılaşılan tipi prolaktinomalardır. Prolaktinomalar hemen her zaman benign olmalarına karşın, prolaktin hipersekresyonuna bağlı gonadal disfonksiyon yapmaları veya kitle etkisine bağlı çevre dokulara bası belirtileri oluşturmaları nedeni ile çoğunlukla tedavi gerektiren durumlardır.

Keywords

Hiperprolaktinemi, prolaktinoma, dopamin agonist tedaviler

An interesting hormon and interesting disease: hyperprolactinemia and prolactinoma

Abstract

Hyperprolactinemia, which is called as a normal release of prolactin hormone (PRL), is the most common pathological condition during endocrinological examinations. The most common type of pituitary adenomas that cause hormone hypersecretion is prolactinoma. Prolactinoma are almost always benign, but require treatment due to prolactin hypersecretion or gonadal dysfunction due to hypersecretion.

Keywords

Hyperprolactinemia, prolactinoma, dopamine agonist treatments

References

• Schlechte JA. Update in Pituitary 2010. Journal of Clinical Endocrinology & Metabolism 2011; 96: 1-8.
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Ban-bury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72(3): 377-82.
• Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91(12): 4769-75.
• Randall RV, Laws ER, Abboud CF, ve ark. Transsphenoidal microsurgical treatment of prolactin producing pituitary adenomas. Mayo Clin Proc 1983; 58:108-21.
• Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol 1994; 41: 359-64.
• Melmed S, Casanueva FF, Hoffman AR, ve ark. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(2): 273-88.
• Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003; 349(21): 2035-41.
• Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68(2): 412-8.
• Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab, 2009; 23: 575–96.
• Diagnosis and treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 273-88.
• Horvath J, Fross RD, Kleiner-Fisman G, ve ark. Severe multivalvularheart disease: a new complication of the ergot derivative dopamine-agonist. Mov Disord 2004; 19: 656–62.
• Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D’Andrea M, Guerra E,Pivonello R, Lerro G, Increased prevalence of tricuspid regurgitation inpatients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008; 93: 3777-84.
• Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Marsan NA. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up Clinical Endocrinology, 2012; 77: 99-105.
• Boguszewski CL, dos Santos CMC, Sakamoto KS, Marini LC. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas Pituitary, 2012; 15: 44–49.
• Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol. 2004; 29: 707-769.
• Hwang P, Guyda H & Friesen H. A radioimmunoassay for human prolactin. Proc Natl Acad Sci USA 1971; 68: 1902–6.
• Sinha YN. Structural variants of prolactin: occurrence and physiological significance. EndocrRev 1995; 16(3): 354–69.
• Keeler C, Dannies PS & Hodsdon ME. The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 2003; 328: 1105–21.
• Cooke NE, Coit D, Shine J, ve ark. Human prolactin cDNA structural analysis and evolutionary comparisons. J Biol Chem 1981; 256: 4007–16.
• Adamson AD, Fieddrichsen S, Semprini S, ve ark. Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-a signaling. Endocrinology 2007; 149: 687–94.
• Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87: 6934–8.
• Freeman ME, Kanyicska B, Lerant A, ve ark. PRL: structure, function, and regulation of secretion. Physiol Rev 2000; 80(4): 1523–631.
• Kleinberg DL. Endocrinology of mammary development, lactation and galactorrhea. In DeGroot LJ, Jameson JL, eds. Endocrinology, 4th ed. Philadelphia: WB Saunders, 2000: 2464-75.
• Tyson JE, Hwang P, Guyda H. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113: 14-20.
• Demura R, Ono M, Demura H, Shizume K, Oouchi H. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. J Clin Endocrinol Metab. 1982; 54: 1246-50.
• Melmed S, Kleinberg D. Anterior Pituitary. In: Kronenberg HM, Larsen PR, Melmed S,Polonsky KS. Williams Textbook of Endocrinology, 11th Ed. Philadelphia: Saunders Elsevier 2008: 180-92.
• Molinari C, Grossini E, Mary DA, ve ark. Prolactin induces regional vasoconstriction through beta-2-adrenergic and nitric oxide mechanisms. Endocrinology 2007; 148: 4080–90.
• Leanos-Miranda A, Marquez-Acosta J, Cardenas-Mondragon GM, ve ark. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab 2008; 93: 2492–9.
• Zhang L, Curhan GC, Forman JP. Plasma prolactin level and risk of incident hypertension in postmenopausal women. J Hypertens 2010; 28: 1400–5.
• McClure CK, Catov JM, Ness RB, Schwarz EB. Lactation and maternal subclinical cardiovascular disease among premenopausal women. Am J Obstet Gynecol 2012; 207: 46.e1–8.
• Carrero JJ, Kyriazis J, Sonmez A. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012; 7: 207–15.
• Pathipati P, Gorba T, Scheepens A, ve ark. Growth hormone and prolactin regulate human neural stem cell regenerative activity. Neuroscience 2011; 190: 409–27.
• Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012; 11: 465-70-.
• Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci 1999; 876: 119–30.
• Park S, Kim da S, Daily JW, Kim SH. Serum prolactin concentrations determine whether they improve or impair b-cell function and insulin sensitivity in diabetic rats. Diabetes Metab Res Rev 2011; 27: 564–74.
• Glasow A, Breidert M, Haidan A. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J Clin Endocrinol Metab, 81: 3103–11.
• Horseman ND. Prolactin. In DeGroot LJ, Jameson JL. Endocrinology, 4th edition. Philadelphia: WB Saunders, 2001: 209-20.
• Cooke NE. Prolactin: normal synthesis, regulation and actions. In DeGroot LJ, Besser GM,Cahill GFJ. Endocrinology. Philadelphia: WB Saunders, 1989; 384-407.
• Reichlin S. TRH: Historical aspects. Ann N Y Acad Sci 1989; 553: 1-6.
• Di Renzo G, Amoroso S, Tagliatela M. 1989. Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. Eur J Pharmacol. 1989; 162: 371-73.
• Muller EE, Locatelli V, Cella S, Peñalva A, Novelli A, Cocchi D. Prolactin lowering and releasing drugs. Mechanisms of action and therapeutic applications. Drugs. 1983; 25: 399-432.
• Benker G, Jaspers C, Hausler G, Reinwein D. Control of prolactin secretion. Klin Wochenschr. 1990; 68: 1157-67.
• Veldhuis JD, Johnson ML. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. J Clin Endocrinol Metab. 1988; 67: 116-23.
• Casanueva FF, Molitch ME, Schlechte JA, ve ark. Guidelines of the Pituitary Society for the diagnosis and management of prolactinoma. Clin Endocrinol (Oxf) 2006; 65(2): 265–73.
• Hattori N. Macroprolactinemia: a new cause of hyperprolactinemia. J Pharmacol Sci 2003; 92: 171-77.
• Glezer A, Soares CR, Vieira JG, Giannella-Neto D, Ribela MT, Goffin V, Bronstein MD. Human macroprolactin displays low biological activity via its homologous receptor in a new sensitive bioassay. J Clin E ndocrinol Metab 2006; 91: 1048-55.
• Olukoga AO, Kane JW. Macroprolactinemia: validation and application polyethylene glycol test and clinical caracterization of the condition. Clin Endocrinol 1999; 51: 119-26.
• Kudryavtsev AN, Krasitskaya VV, Petunin AI, Burakov AY, Frank LA. Simultaneous bioluminescent immunoassay of serum total and Ig G-bound prolactins. Anal Chem. 2012; 84: 3119-24.
• Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002; 20(4): 365-74.
• Vance ML, Thorner MO. Prolactinomas. Endocrinol Metab Clin North Am 1987; 16: 731-53.
• Bahamondes L, Faundes A, Tambascia M, Trevisan M, Dachs JN, Pinotti JA. Menstrual pattern and ovarian function in women with hyperprolactinemia. Int J Gynaecol Obstet 1985; 23: 31-6.
• Prabhakar VK, Davis JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol. 2008; 22(2): 341-53.
• Sartorio A, Pizzocaro A, Liberati D, De Nicolao G, Veldhuis JD, Faglia G. Abnormal LH pulsatility in women with hyperprolactinemic amenorrhea normalizes after bromocriptine treatment: deconvolution-based assessment. Clin Endocrinol. 2000; 52: 703-12.
• Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: response to bromocriptine. J Clin Endocrinol Metab 1984; 59: 941-8.
• Salenave S, Trabado S, Maione L, Brailly-Tabard S, Young J. Male acquired hypogonadotropic hypogonadism: Diagnosis and treatment. Ann Endocrinol 2012; 73(2): 141-6.
• Saito T, Saxena BB. Specific receptors for prolactin in the ovary. Acta Endocrinol. 1975; 80: 126-37.
• Dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC,Gadelha MR. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 2011; 19(4): 800-5.
• Ling C, Svensson L, Ode´n B, Weijdegård B, Edén B, Edén S, Billig H. Identification of functional prolactin (PRL] gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. 2003; 88(4): 1804-8.
• Asai-Sato M, Okamoto M, Endo M. Hypoadiponectinemmia in lean lactating women: prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 2006; 53: 555-62.
• Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab, 1988; 67: 124-30.
• Mancini T, Casanueva FF, Giustina A Hyperprolactinemia and prolactinomas.Endocrinol Metab Clin North Am 2008; 37: 67-99.
• Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007; 3(5): 929-51.
• Johnsen E, Kroken RA, Abaza M, Olberg H, Jørgensen HA. A ntipsychotic-induced hyperprolactinemia: a crosssectional survey. J Clin Psychopharmacol 2008; 28: 686-90.
• Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1978-81.
• Molitch ME. Medication-induced hyperprolactinemia. Mayo Clinic Proceedings, 2005; 80: 1050-7.
• Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 1980; 50: 846-52.
• Keye WR, Yuen BH, Knopf RF, Jaffe RB. A menorrhea, hyperprolactinemia and pituitary enlargement secondary to primary hypothyroidism. Successful treatment with thyroid replacement. Obstet Gynecol 1976; 48: 697-702.
• Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified nonfunctionin macroadenoma. Clin Endocrinol (Oxf)2006; 65: 524-9.
• Bonert VS, Melmed S. Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab, 2006; 2: 408-12.
• Hattori N, Ishihara T, Saiki Y. Macroprolactinaemia: prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol. 2009; 71(5): 702-8.
• Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005; 8(1): 3-6.
• Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 2002; 97: 299-306.
• Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol 2003; 58: 662-70.
• Buurman H, S aegerW. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 2006; 154: 753-8.
• Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A,Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003; 148: 325-31.
• Colao A, Loche S. Prolactinomas in children and adolescents. Endocr Dev. 2010; 17: 146-59.
• Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 2007; 157: 371-82.
• Burgess JR, Shepard JJ, Parameswaran V, Hoffman L, Greenaway TM. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. J Clin Endocrinol Metab 1996; 81: 1841-5.
• Verges B, Boureille F, Goudet P, ve ark. Pituitary disease inMENtype 1 (MEN1): data from the France-BelgiumMEN1multicenter study. J Clin Endocrinol Metab 2002; 87(2): 457–65.
• Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485–534.
• Weiss MH, Teal J, Gott P, Wycoff R, Yadley R, Apuzzo ML, Giannotta SL, Kletzky O,March C. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983; 12: 180-3.
• Colao A. Annunziato L & Lombardi G. Treatment of prolactinomas. Ann Med 1998; 30: 452-9.
• Ogilvie CM, Milsom SR. Dopamine agonists in the treatment of prolactinoma-are they still first choice? Intern Med J. 2010; 40(2): 156-61.
• Colao A, Di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002; 11: 787-800.
• Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Eng J Med 1986; 315: 542-6.
• De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998; 138: 286-93.
• Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab, 2001; 86: 5256-25.
• Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord. 2009; 10(2): 111-23.
• Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists:J Clin Endocrinol Metab 2000;85:22.
• Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas: N Engl J Med 1985: 313: 656-9.
• Lamberts SW, Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab.1991; 72: 635-41.
• Dallabonzana D, Liuzzi A, Oppizzi G, Cozzi R, Verde G, Chiodini P, Rainer E, Dorow R, Horowski R. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J Clin Endocrinol Metab. 1986; 63: 1002-7.
• Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J 1984; 289: 1101-3.
• Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007; 356: 39-46.
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
• Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular disease. Lancet 2009; 374: 577-85.
• Valassi E, Klibanski A, Biller BM. Clinical Review: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010, 95(3): 1025-33.
• Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Salvetti A, Martino E. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients withhyperprolactinaemia. IntJ Clin Pract 2008;62:18.
• Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008; 159: R11-14.
• Devin JK, Lakhani VT, Byrd III BF, Blevins LS Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract, 2008; 14: 672-7.
• Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008; 93: 3348-56.
• Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A.. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008; 159: 1-5.
• Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010; 72(1): 53-8.
• Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol 2009; 70: 104-8.
• Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009; 12: 153-7.
• Molitch ME. J Clin Endocrinol Metab 93: 4643-4645.
• Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. 2011; 114(5): 1369-79.
• Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002:87:3180-86.
• Sinha S, Sharma BS, Mahapatra AK. Microsurgical management of prolactinomas clinical and hormonal outcome in a series of 172 cases. Neurol India. 2011: 59(4); 532-6.
• McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4: 72-80.
• Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature. 1988; 332: 78-81.
• Kruger S, Hoffmann R, Graf J, ve ark. Brain natriuretic Peptide. Diagnostic and prognostic value in chronic heart failure. Med Klin (Munich) 2003; 98: 562-567.
• Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998; 32: 22-28.
• Friedl W, Mair J, Thomas S, Pichler M, Puschendorf B. Natriuretic peptides and cyclic guanosine 3’, 5’-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Heart 1996; 76: 129-136.
• Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 992; 130: 229-239.
• Raine AE, Erne P, Burgisser E, ve ark. Atrial natriuretic peptide ve atrial pressures in patients with kongestive heart failure. N Engl J Med. 1986; 315: 533-537.
• Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999; 230: 132-142.
• Davidson NC, Naas AA, Hanson JK, Kennedy NS, Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol. 1996; 77: 828-831.
• Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992; 86: 1081-1088.
• Mukoyama M, Nakao K, Hosoda K, ve ark. Brain natriuretic peptide as a novel cardiac hormone in homans. Evidence for an exquisite dual natriuretic peptide system atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
• Charles CJ, Espiner EA, Nicholls MG, ve ark. Clearence receptors and endopeptidase 24.11: Equal role in natriuretic peptide metobolism in conscious sheep. Am J Physiol 1996; 271: 373-380.
• Roques BP, Noble F, Dauge V, Fournie Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: Structure, inhibition and experimental and clinical pharmacology. Pharmacol Rev 1993; 45: 87-146.
• Mair J, Friedl W, Thomas S, Pushendorf B. Natriüretic peptides in assessment of left ventricular dysfunction. Scandinavian Journal of Clinical and Laboratory İnvestigation.1999; 59: 132-142.
• Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M, Giannessie D. The circulating levels of cardiac natriuretic peptide hormones in healty adults; effects of age and sex. Clin Chem Lab Med 2002; 40: 371-377.
• Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, ve ark. Impact of age and sex on natriuretic peptide levels in healty adults. Am J Cardiol 2002; 90: 254-258.
• Taemura G, Fujifars H, Horike K. Ventricular expression of atrial natriuretic polypeptide and its relations with the hemodynamics and histology in dilated human hearts. Circulation 1989; 80: 1137-1147.
• Yandle T. Biochemistry of natriuretic peptides. Intern Medi 1994; 135: 561-576.
• Yamamoto K, Burnett JC Jr, Jougasaki M ve ark. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-994.
• Maisel AS, Krishnaswamy P, Nowak RM ve ark. Breathing Not Properly Multinational Study Investigators. Rapid measurament of B-Type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002: 347; 161-167.
• Yasue H, Yashimura M, Sumida H. Localiztion and mechanism of secretion of B type natriuretic peptide in comparison with those of A type natriuretic peptide in normal subjects and patiens with heart failure. Circulation 1994; 90: 195-203.
• Yoshimura M, Yasue H, Okumara K, Ogawa H, Jougasaki M, Mukoyama M, ve ark. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-469.
• Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. general population. Heart 2003; 89: 745.
• Leowattana W, Sirithunyanot C, Sukumalchantra Y, Chaisupamonkollarp S,Watanaawaroon S, Chivatanaporn B, ve ark. Serum N-terminal pro-brainnatriuretic peptide in normal Thai subjects. J Med Assoc Thai, 2003; 86 (Suppl1): 46-51.
• Maisel A, Hollander JE, Guss D, ve ark. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter Study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004; 44: 1328-1333.
• Januzzi JL Jr, Camargo CA, Anwaruddin S, ve ark. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005; 95: 948-954.
• Eric J Topol. Textbook of cardiovacular medicine. 2002: 1091-165.
• Feigenbaum H, Armstrong WF, Ryan T. Feigenbaum’s Echocardiography 2005: 11-45.
• DeMaria AN, Blanchard DG. The echocardiogram. In: Fuster V, Alexander RW. O’rourke RA eds. Hurst’s The Heart: Echocardiogram. 11th ed. New York: McGraw-Hill; 2004; 351-65.
• Litwin SE, Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol 1993; 22:49-55.
• Yen SSC. A contemporary overview. In: Adashi EY, Rock JA, Rosenwaks Z, eds. Reproductive endocrinology, surgery, and technology. Philadelphia: Lippincott-Raven 1996; 1117–1126.
• Krishnamoorthy VK, Sengupta PP, Gentile F, Khandheria B. History of echocardiography and its future applications in medicine. Crit Care Med 2007; 35: 309-13.
• Isaaz K, Thompson A, Ethevenot G, Cloez JL, Brembilla B, Pernot C. Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol 1989; 64: 66–75.
• McDicken WN, Sutherland GR, Moran CM, Gordon L. Colour doppler velocity imaging of the myocardium. Ultrasound Med Biol 1992; 18: 651-4.
• Terzioğlu M. Kalp Siklusu. In: Terzioğlu M, Yiğit G, Oruç T. Fizyoloji Ders Kitabı, 2. Baskı. 1993; 10: 253-60.
• Garcia-Fernandez MA, Azevedo J, Moreno M, ve ark. Segmental isovolumic relaxation time of the left ventricular myocardium by pulsed Doppler tissue imaging: a new index of regional diastolic function and normal pattern description. Eur Heart J, 1996.
• Nagueh SF, Middleteon KJ, Kopelen HA, ve ark. Doppler Tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533.
• Waggoner AD, Bierig SM. Tissue Doppler imaging: a useful echocardiographic metod for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr 2001; 14: 1143-52.
• Maron BJ, Nishimura RA, McKennaWJ, et al: Assesment of permanent dualchamberpacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 99: 2927, 1999.
• Pravin M. Shah: Hypertrophiccardiomyopathy and diastolic dysfunction. J Am Coll Cardiol, 2003; 42: 286-287.
• Farias CA, Rogriguez L, Garci MJ, ve ark. Assessment of diastolic function by tissue Doppler echocardiography: comparison with standard transmitral and pulmonary venous flow. J Am Soc Echocardiogr 1999; 12: 609-617.
• Matsumura Y, Elliott P M, Virdee M S, et al. Left ventricular diastolic function assessed usung doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity: Heart 2002; https://doi.org/87;247-251.
• Naqvi TZ, Neyman G, Broyde A ve ark. Comparison of tissue Doppler with conventional transmitral Doppler: Noninvasive in left ventricular hypertrophy. J Am Soc Echocardiogr 2001; 14: 1153-1160.
• Matthews DR,Hosker JP,Rudenski AS,Naylor BA,Treacher DF,Turner RC. Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
• Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, American Society of Echocardiography 2003 Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003 Jul;16(7):777-802.
• Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE,Morreau H, Smit JW, Romijn JA, Bax JJ 2004 Increased prevalence of regurgitantvalvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71–75.
• Maisel AS, Krishnaswamy P, Nowak RM, ve ark. Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med 2002; 347: 161-7.
• Stanek B, Frey B, Hulsmann M, ve ark. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001, 38: 436-42.
• Wanaga Y, Nishi I, Furuichi S, ve ark. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47: 742-8.
• Gerber IL, Stewart RA, Legget ME, ve ark. Increased plasma natriureticpeptide levels reflect symptom onset in aortic stenosis. Circulatio0, 2003; 107: 1884-90.
• Weber M, Arnold R, Rau M, ve ark. Relation of N-terminal pro B-typenatriuretic peptide to progression of aortic valve disease. Eur Heart J, 2005; 26: 1023-30.
• Bergler-Klein J, Klaar U, Heger M, ve ark. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2302-8.
• Weber M, Hausen M, Arnold R, ve ark. Diagnostic and prognostic value ofN-terminal pro B-type natriuretic peptide (NT-proBNP) in patients withchronic aortic regurgitation. Int J Cardiol 2008; 127: 321-7.
• Yoon CH, Zo JH, Kim YJ, ve ark. B-type natriuretic peptide in isolatedsevere tricuspid regurgitation: determinants and impact on outcome.J Cardiovasc Ultrasound 2010; 18: 139-45.
• Cheung D, Heaney A. Dopamin agonist and valvular heart disease. Current Opinion in Endocrinology Diabetes and Obesity 2009; 16: 316–20.
• Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol, 1999: 83: 897–902.
• Choong CY, Abascal VM, Weyman J, Levine RA, Gentile F,1989 Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J, 117: 636–642.
• Verhelst J, ABS R, Maiter D ve ark. Cabergoline in the treatment of hiperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab, 1999; 84: 2518-2522.
• Tuzcu A, Yalaki S, Arikan S, ve ark. Evaluation of insulin sensitivity in hyperprolactinemic subjects Pituitary, 2009, 12: 330–334.